The patients enrolled in this study were selected according to the following criteria: (1) autopsy cases with histologically confirmed metastatic primary lung cancer, (2) death caused by cancer progression, (3) cfDNA extracted from stored plasma samples collected within the 3-month period before death, and (4) written informed consent obtained from the patient during her or his lifetime of the protocol approved by the institutional review board of Kanazawa University Graduate School of Medicine (approval # 327). The protocol for the NGS-based genotyping assays used in tumor tissues and cfDNA from patients with advanced NSCLC applied to specimens obtained at autopsy. We collected the following clinical data: sex, smoking history, diagnosis date, histological type, treatment regimen for lung cancer and ages at diagnosis and death. The study was conducted in accordance with the provisions of the Declaration of Helsinki.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.